Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study: Current status of treatment selection in japan

Takayuki Iwamoto, Naruto Taira, Tomomi Fujisawa, Kazuhiro Araki, Kentaro Sakamaki, Takafumi Sangai, Yuichiro Kikawa, Tadahiko Shien, Shintaro Takao, Masako Sato, Yoshinari Goto, Takashi Yoshida, Masato Takahashi, Tomohiko Aihara, Hirofumi Mukai

Research output: Contribution to journalArticle

Abstract

The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50). Forty-one patients (41/50; 82%) received fulvestrant, 5 patients (10%) received selective estrogen receptor modulators (SERMs), 3 patients (6%) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. Forty-five patients selected their secondary ET based on its therapeutic effect, while 14 patients selected it based on side effects. Most patients with progression after primary ET selected fulvestrant as the secondary ET based on its therapeutic and side effects. We await the final results from the HORSE-BC study.

Original languageEnglish
Pages (from-to)369-374
Number of pages6
JournalActa Medica Okayama
Volume72
Issue number4
Publication statusPublished - Jan 1 2018

Fingerprint

Estrogen Receptors
Japan
Breast Neoplasms
Selective Estrogen Receptor Modulators
Aromatase Inhibitors
Sirolimus
Therapeutics
Therapeutic Uses
fulvestrant
Multicenter Studies
Observational Studies
Safety
Recurrence

Keywords

  • Breast cancer
  • Fulvestrant
  • Low sensitivity
  • Primary endocrine therapy
  • Secondary endocrine therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study : Current status of treatment selection in japan. / Iwamoto, Takayuki; Taira, Naruto; Fujisawa, Tomomi; Araki, Kazuhiro; Sakamaki, Kentaro; Sangai, Takafumi; Kikawa, Yuichiro; Shien, Tadahiko; Takao, Shintaro; Sato, Masako; Goto, Yoshinari; Yoshida, Takashi; Takahashi, Masato; Aihara, Tomohiko; Mukai, Hirofumi.

In: Acta Medica Okayama, Vol. 72, No. 4, 01.01.2018, p. 369-374.

Research output: Contribution to journalArticle

Iwamoto, T, Taira, N, Fujisawa, T, Araki, K, Sakamaki, K, Sangai, T, Kikawa, Y, Shien, T, Takao, S, Sato, M, Goto, Y, Yoshida, T, Takahashi, M, Aihara, T & Mukai, H 2018, 'Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study: Current status of treatment selection in japan', Acta Medica Okayama, vol. 72, no. 4, pp. 369-374.
Iwamoto, Takayuki ; Taira, Naruto ; Fujisawa, Tomomi ; Araki, Kazuhiro ; Sakamaki, Kentaro ; Sangai, Takafumi ; Kikawa, Yuichiro ; Shien, Tadahiko ; Takao, Shintaro ; Sato, Masako ; Goto, Yoshinari ; Yoshida, Takashi ; Takahashi, Masato ; Aihara, Tomohiko ; Mukai, Hirofumi. / Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study : Current status of treatment selection in japan. In: Acta Medica Okayama. 2018 ; Vol. 72, No. 4. pp. 369-374.
@article{6e5922ca3d664488af48eb06aabce7ec,
title = "Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study: Current status of treatment selection in japan",
abstract = "The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84{\%} of patients (42/50) and de novo stage IV breast cancer in 16{\%} (8/50). Forty-one patients (41/50; 82{\%}) received fulvestrant, 5 patients (10{\%}) received selective estrogen receptor modulators (SERMs), 3 patients (6{\%}) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. Forty-five patients selected their secondary ET based on its therapeutic effect, while 14 patients selected it based on side effects. Most patients with progression after primary ET selected fulvestrant as the secondary ET based on its therapeutic and side effects. We await the final results from the HORSE-BC study.",
keywords = "Breast cancer, Fulvestrant, Low sensitivity, Primary endocrine therapy, Secondary endocrine therapy",
author = "Takayuki Iwamoto and Naruto Taira and Tomomi Fujisawa and Kazuhiro Araki and Kentaro Sakamaki and Takafumi Sangai and Yuichiro Kikawa and Tadahiko Shien and Shintaro Takao and Masako Sato and Yoshinari Goto and Takashi Yoshida and Masato Takahashi and Tomohiko Aihara and Hirofumi Mukai",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "369--374",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study

T2 - Current status of treatment selection in japan

AU - Iwamoto, Takayuki

AU - Taira, Naruto

AU - Fujisawa, Tomomi

AU - Araki, Kazuhiro

AU - Sakamaki, Kentaro

AU - Sangai, Takafumi

AU - Kikawa, Yuichiro

AU - Shien, Tadahiko

AU - Takao, Shintaro

AU - Sato, Masako

AU - Goto, Yoshinari

AU - Yoshida, Takashi

AU - Takahashi, Masato

AU - Aihara, Tomohiko

AU - Mukai, Hirofumi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50). Forty-one patients (41/50; 82%) received fulvestrant, 5 patients (10%) received selective estrogen receptor modulators (SERMs), 3 patients (6%) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. Forty-five patients selected their secondary ET based on its therapeutic effect, while 14 patients selected it based on side effects. Most patients with progression after primary ET selected fulvestrant as the secondary ET based on its therapeutic and side effects. We await the final results from the HORSE-BC study.

AB - The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50). Forty-one patients (41/50; 82%) received fulvestrant, 5 patients (10%) received selective estrogen receptor modulators (SERMs), 3 patients (6%) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. Forty-five patients selected their secondary ET based on its therapeutic effect, while 14 patients selected it based on side effects. Most patients with progression after primary ET selected fulvestrant as the secondary ET based on its therapeutic and side effects. We await the final results from the HORSE-BC study.

KW - Breast cancer

KW - Fulvestrant

KW - Low sensitivity

KW - Primary endocrine therapy

KW - Secondary endocrine therapy

UR - http://www.scopus.com/inward/record.url?scp=85051861681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051861681&partnerID=8YFLogxK

M3 - Article

C2 - 30140084

AN - SCOPUS:85051861681

VL - 72

SP - 369

EP - 374

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -